-
Domestic PD-1 therapy! Baiji Shenzhou Baizean ® first-line combination of chemotherapy treatment of non-squamous lung cancer (NSCLC) Phase III clinical success!
Time of Update: 2020-04-14
April 14, 2020 / Biovalley BIOON/ -- BeiGene announced that the evaluation of anti-PD-1 therapy Beizean ® (tilelizumab, terrier-beadmono injection) combined with pemericeand and platinum first-lin
-
JAMA Oncol: Shock! Mothers with more than 30% less risk of ovarian cancer after more than 1 year of breastfeeding
Time of Update: 2020-04-14
15 April 2020 / Biovalley BIOON/- An international study found that women who breastfed their babies had a nearly 25 percent lower risk of developing ovarian cancer studies also show that the long
-
Nature Cancer: Breakthrough! New method transforms colon cancer cells into normal cells!
Time of Update: 2020-04-14
April 14, 2020 /PRNewswire 2020 / -- Using an improved natural substance and current methods could improve the treatment of colon cancer, according to biologists at the University of California, Ir
-
Nat Med: Clinical trials show preoperative immunotherapy is effective for colon cancer patients
Time of Update: 2020-04-14
"Our surgeons were very enthusiastic from the start, otherwise we wouldn't have been able to do this clinical trial ," Chalabi said "Therefore, the primary purpose of the NICHE study was to confirm that the operation was safe and scheduled and that there would be no more postoperative complications than expected--- Can surgery be saved?
-
New Study on Tumor Immunotherapy: Near-Infrared Light Immunotherapy Drugs
Time of Update: 2020-04-13
the development of cancer drugs has been one of the most important goals in the field of drug research and development, for tumor physiological mechanism of different links, researchers have issu
-
China's urinary skin cancer (UC) the first PD-(L)1 treatment! Baiji Shenzhou Baize an ® (for Reli Zuma mono-resistance) was approved the 2nd indication!
Time of Update: 2020-04-11
The ® has been approved by the State Drug Administration (NMPA) for the treatment of patients with recurrent or incurable classic Hodgkin's lymphoma with at least second-line system chemotherapy, as well as platinum-containing chemotherapy failures for the treatment of PD-L1 high expression, including localized advanced or metastatic urinary tract cancer patients within 12 months of advances in new or assisted chemotherapy.
-
First-line immunotherapy for bladder cancer! Merck/Pfizer Bavencio is eligible by the FDA for breakthrough drug review in real time!
Time of Update: 2020-04-10
April 10, 2020 / PRNewswire BIOON/ -- Pfizer and partner Merck KGaA have jointly announced that they have filed a supplementary biologics license application (BLA) with the U.S Food and Drug Admi
-
CD20xCD3 bispecific antibody! Regeneration Yuan and Reding Pharmaceuticals reached a strategic cooperation, Greater China to develop REGN1979 treatment B cell tumors!
Time of Update: 2020-04-09
09 April 2020 / Biovalley BIOON / -- Regeneron and Zai Lab recently jointly announced that the two sides have reached a strategic cooperation on the development and commercialization of a CD20xCD3
-
Nature Sub-journal: Lysosome abnormalities cause cancer!
Time of Update: 2020-04-09
April 9, 2020 / Biovalley BIOON / - Cancer cells grow and split in an uncontrolled manner A new study from Uppala University shows that changes in cell degradation centers, called lysosomes, can ca
-
Biophysical J: New Discovery in Cancer Treatment! Cancer cells actually inject substanceinto into other cells!
Time of Update: 2020-04-09
April 9, 2020 / Biovalley BIOON / - Although most cancer cells are killed by chemotherapy, individual cells are sensitive differently, so some cancer cells often escape Therefore, the diversity of
-
Lung cancer first-line new program! BMS star immune combination Opdivo-Yervoy combined with limited course of chemotherapy protocol snare snare snare snr in the US and EU goes into review!
Time of Update: 2020-04-09
09 April 2020 / Biovalley BIOON/ -- The U.S Food and Drug Administration (FDA) has accepted an application for a supplementary biologics license (BLA) to treat The Opdivo," a therapeutic anti-PD-1
-
"Broad spectrum" tumor immunotherapy! The application for the second unlimited cancer species in Mercadon Keytruda is reviewed by the FDA!
Time of Update: 2020-04-08
April 08, 2020 / prnewswire BIOON/ -- Merck and Co recently announced that the U.S Food and Drug Administration ( FDA ) has accepted and granted priority review to a supplemental biological produ
-
The first triple-negative breast cancer ADC drug! Sacituzumab govitecan validation Phase III study has significant efficacy, early termination!
Time of Update: 2020-04-08
08 April 2020 / Biovalley BIOON/-- Immunomedic is a clinical biopharmaceutical company focused on developing monoclonal antibody-based therapies for targeted treatments for cancer and other serious
-
Redefining the first-line treatment of lymphoma! Takeda CD30 target drug Adcetris EU approved in the treatment system to become large cell lymphoma (sALCL)
Time of Update: 2020-04-07
07 April 2020 / Biovalley BIOON / -- Takeda Pharmaceuticals recently announced that the European Medicines Agency (EMA) Committee on Human Medicine products (CHMP) has issued an active review reco
-
Nature Sub-journal: Genetic mutations in Asian population sedlead malignant head and neck and lung cancer
Time of Update: 2020-04-07
April 7, 2020 / Bio-Valley BIOON /-- Researchers at the Singapore Institute of Cancer Science (CSI Singapore) at the National University of Singapore (NUS) have discovered a genetic mutation called
-
EMBO Rep: Discovering a new immune brake --- EGR4, promising new anti-cancer immunotherapy
Time of Update: 2020-04-05
April 5, 2020 /PRNewswire BIOON/--- Immune System is like a carefully tuned machine with its own built-in "brake" that prevents it from overreacting and causing excessive inflammation in otherwise h
-
Nature Sub-journal: New breakthrough in the fight against cancer! Kill cancer cells by swelling the lysosomes!
Time of Update: 2020-04-05
April 5, 2020 / Biovalley BIOON /-- nano particles are covered with a mixture of positive and negative electricity ligands, clustered in the super-conditor of cancer cell lysosomes, destroying th
-
Colorectal cancer heavyweight news! Mercadon Keytruda first-line treatment of MSI-H/dMMR patients head-to-head Phase III clinical efficacy beats standard chemotherapy!
Time of Update: 2020-04-03
, , 2020 /PRNewswire BIOON/ -- Merck and Co recently announced the evaluation of the first-line treatment of the anti-PD-1 therapy Keytruda (Korida, generic name: pembrolizumab, Pablo Zumab, Pablo
-
Lung cancer! AstraZeneca Imfinzi (Infyfan) is approved by the U.S. FDA for first-line treatment of wide-stage small cell lung cancer (ES-SCLC)!
Time of Update: 2020-03-31
March 30 , 2020 /PRNewswire BIOON/ -- AstraZeneca recently announced that the U.S Food and Drug Administration ( FDA ) has approved the anti-PD-L1 therapy Imfinzi (Infyin) Van, generic name: durva
-
Nature: Revealing That ILC2 Cells Enhance The Efficacy of Anti-PD-1 Immunotherapy
Time of Update: 2020-03-30
March 30, 2020 / PRNewswire BIOON/--- Congenital Lymphocytes (innate lymphoid cell, ILC), also known as inherent immune cells, is a type of lymphocyte subgroup that differs from T-cells and B-cells
